Table 1.
Specification of breast cancer cell lines used in the experiments.
Figure 1.
IHC analysis of T-STAR on primary invasive breast cancer where A) shows a negative case, B) a case with cytoplasmic staining and C) a case with nuclear T-STAR staining.
Table 2.
T-STAR nuclear and cytoplasmic expression in relation to patient- and tumor characteristics in the total cohort (χ2 test for linear trend).
Figure 2.
Kaplan-Meier curves showing T-STAR expression correlated to survival.
A) Nuclear T-STAR expression in all cases. B) Nuclear T-STAR expression in ER+ cases only. C) Cytoplasmic T-STAR expression in all cases. D) Cytoplasmic T-STAR expression in ER+ cases only.
Figure 3.
Kaplan-Meier curves correlating T-STAR expression to survival using a dichotomized variable where any nuclear staining and intensity have been grouped together.
A) Showing T-STAR expression in all cases. B) Showing T-STAR expression in ER+ cases only.
Table 3.
Cox uni- and multivariate analysis of Recurrence Free Survival according to nuclear T-STAR expression.
Figure 4.
Increased proliferation after knock-down of T-STAR in five breast cancer cell lines.
A) Reduction in T-STAR mRNA levels after knock-down as assessed by RT-qPCR. B) Representative data showing, reduction (17%) in T-STAR protein levels (WB) compared to wt (130%) and scrambled control cells (100%) in the L56Brc1cell line after knock-down. C) Increased proliferation at 48 h (JIMT-1, MDA-MB-231 and L56Br-C1) or 72 h (PMC42 and SKBR-3) after knock-down compared to the scrambled control using thymidine incorporation (measured as cpms (counts per minutes)). Of note, values for JIMT-1 are scaled by a factor 10 for the clarity of presentation. D) An increase in proliferation was also seen measured by the WST-1 assay after 48 h (JIMT-1 and MDA-MB-231) or 72 h (PMC42, L56Br-C1 and SKBR-3). Significance is marked by a * where the p-value ≤0.05 and ** when ≤0.01.
Figure 5.
Decreased proliferation after overexpression of T-STAR in five breast cancer cell lines.
A) Increased T-STAR mRNA levels after overexpression measured by RT-qPCR. B) Increased (676%) T-STAR protein level (WB) compared to GFP (16%) and wt (100%) control cells in the MDA-MB-231 cell line after overexpression. C) A decrease in proliferation could be detected at 48 h after overexpressing T-STAR using thymidine incorporation and D) after 48 h (PMC42, L56Br-C1 and T47D) or 72 h (JIMT-1 and MDA-MB-231) upon assessment of enzymatic activity (WST-1 assay). Significance is marked by a * where the p-value ≤0.05 and ** when ≤0.01.